Ultima Genomics Unveils ppmSeq Technology for Enhanced ctDNA Detection at AACR
Ultima Genomics has presented new findings at the American Association for Cancer Research (AACR) meeting, showcasing its ppmSeq technology for detecting minimal residual disease (MRD) in cancer patients. The technology aims to identify small numbers of cancer cells remaining after treatment, which is crucial for assessing treatment effectiveness and relapse risk. The TRACERx study, one of the largest tumor evolution studies funded by Cancer Research UK, is a key component of this research. It involves sequencing genetic data from over 3,200 tumor samples from more than 800 lung cancer patients. The study's findings, presented by Charles Swanton from The Francis Crick Institute, highlight the high sensitivity of ppmSeq in detecting circulating tumor DNA (ctDNA) at low concentrations. This advancement could significantly improve MRD monitoring and potentially be deployed on a larger scale. 
